FPI-2059

N/A

Report date: 2025/09/22 17:35:12

Base Information

Drug NameFPI-2059
Drug Alias Name225-AcIPN-1087FPI-2059225-AcIPN-01087[225]-FPI-2059[225Ac]3BP-227 +[6] 
ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225Ac +[4] 
Mechanisms of ActionNeurotensin receptor 1 modulators
TargetsNeurotensin receptor 1
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsStomach Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIpsen BiopharmaFusion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFusion Pharmaceuticals Inc3B Pharmaceuticals GmbH
Active IndicationsN/A
Inactive IndicationsSolid tumoursProstatic NeoplasmsStomach Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A